Clinical-stage biotechnology company Abivax SA (Euronext Paris:ABVX) (Nasdaq:ABVX) said on Friday that it will make changes to its Phase 2 development programme for obefazimod in Crohn's Disease (CD) after feedback from the US Food and Drug Administration (FDA).
Abivax will modify the trial design taking into account FDA recommendations and conduct a dose ranging Phase 2b clinical trial.
Patient enrolment is expected to start in the third quarter of 2024.
The Phase 2b trial will be double-blind and placebo-controlled, evaluating three obefazimod doses over a 12-week induction period followed by a 40-week maintenance period.
These adjustments are based on initial Phase 2a IND submission feedback. Abivax does not expect the changes to impact the overall programme budget and projected supplemental New Drug Application (sNDA) submission timeline.
Pierre Fabre Pharmaceuticals reports FDA acceptance and Priority Review of Tabelecleucel BLA
Bavarian Nordic's chikungunya vaccine receives validation from EMA for accelerated review
Atara Biotherapeutics gains FDA Priority Review for tabelecleucel
Hyperfine secures FDA clearance for faster brain imaging software
Silo Pharma agrees Alzheimer's drug licence
Kyverna's KYV-101 granted FDA Regenerative Medicine Advanced Therapy designation
Camurus reports positive Phase 3 ACROINNOVA 2 results
Acurx Pharmaceuticals presents positive Ibezapolstat Phase 2 clinical trial results for CDI